Stay updated on Sotagliflozin Impact on CV Events in T2D Post HF Clinical Trial
Sign up to get notified when there's something new on the Sotagliflozin Impact on CV Events in T2D Post HF Clinical Trial page.

Latest updates to the Sotagliflozin Impact on CV Events in T2D Post HF Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.3.4 was added to the history and Revision: v3.3.3 was removed.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe new page footer shows Revision: v3.3.3 and removes HHS Vulnerability Disclosure as well as Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page history shows a new revision entry (v3.3.2) and removal of the previous revision (v3.2.0).SummaryDifference0.1%

- Check60 days agoChange DetectedThe government funding/operating status notice shown on the page has been removed. This change does not affect the study data, version history, or how users access information on the page.SummaryDifference0.4%

- Check74 days agoChange DetectedOld and New screenshots show the same record history for NCT03521934; only the visual layout appears different, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check103 days agoChange DetectedSummary: The page now displays a funding-status notice and announces a major version upgrade to v3.2.0, replacing the previous v3.1.0.SummaryDifference9%

Stay in the know with updates to Sotagliflozin Impact on CV Events in T2D Post HF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sotagliflozin Impact on CV Events in T2D Post HF Clinical Trial page.